These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
330 related items for PubMed ID: 2320079
1. Mitochondrial myopathy caused by long-term zidovudine therapy. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. N Engl J Med; 1990 Apr 19; 322(16):1098-105. PubMed ID: 2320079 [Abstract] [Full Text] [Related]
2. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy. Grau JM, Masanés F, Pedrol E, Casademont J, Fernández-Solá J, Urbano-Márquez A. Ann Neurol; 1993 Aug 19; 34(2):206-11. PubMed ID: 8338345 [Abstract] [Full Text] [Related]
3. Characteristics and pathogenesis of myositis in human immunodeficiency virus infection--distinction from azidothymidine-induced myopathy. Espinoza LR, Aguilar JL, Espinoza CG, Gresh J, Jara J, Silveira LH, Martinez-Osuna P, Seleznick M. Rheum Dis Clin North Am; 1991 Feb 19; 17(1):117-29. PubMed ID: 2041882 [Abstract] [Full Text] [Related]
6. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished? Simpson DM, Citak KA, Godfrey E, Godbold J, Wolfe DE. Neurology; 1993 May 19; 43(5):971-6. PubMed ID: 8492955 [Abstract] [Full Text] [Related]
12. Cytokine expression in the muscle of HIV-infected patients: evidence for interleukin-1 alpha accumulation in mitochondria of AZT fibers. Gherardi RK, Florea-Strat A, Fromont G, Poron F, Sabourin JC, Authier J. Ann Neurol; 1994 Nov 19; 36(5):752-8. PubMed ID: 7979221 [Abstract] [Full Text] [Related]
13. The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study. Stambuk D, Youle M, Hawkins D, Farthing C, Shanson D, Farmer R, Lawrence A, Gazzard B. Q J Med; 1989 Feb 19; 70(262):161-74. PubMed ID: 2512592 [Abstract] [Full Text] [Related]
14. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Mhiri C, Baudrimont M, Bonne G, Geny C, Degoul F, Marsac C, Roullet E, Gherardi R. Ann Neurol; 1991 Jun 19; 29(6):606-14. PubMed ID: 1892364 [Abstract] [Full Text] [Related]
15. Type B lactic acidosis in an AIDS patient treated with zidovudine. Aggarwal A, al-Talib K, Alabrash M. Md Med J; 1996 Nov 19; 45(11):929-31. PubMed ID: 8942169 [Abstract] [Full Text] [Related]
17. Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine. Manji H, Harrison MJ, Round JM, Jones DA, Connolly S, Fowler CJ, Williams I, Weller IV. J Neurol; 1993 Sep 19; 240(8):479-88. PubMed ID: 8263554 [Abstract] [Full Text] [Related]
18. [A clinical, histochemical and ultrastructural study of mitochondrial myopathy]. Jiang XM. Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1990 Oct 19; 23(5):297-9, 320. PubMed ID: 2178086 [Abstract] [Full Text] [Related]
20. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro. Semino-Mora MC, Leon-Monzon ME, Dalakas MC. Lab Invest; 1994 Jul 19; 71(1):102-12. PubMed ID: 7518879 [Abstract] [Full Text] [Related] Page: [Next] [New Search]